Comunicados de prensa
menu
Synthon en el mundo
En el mundo
otros sitios web de synthon
Corporate
(inglés)
Chequia
(checo)
España
(español)
Rusia
(ruso)
Argentina
(español)
España
(catalán)
México
(español)
Chile
(Spanish)
S
Synthon México
N
Nuestro negocio
Inicio
Farmacovigilancia
Súmate a Synthon
Contacto
Registro de Profesionales de la Salud
Comunicados de prensa
16 sept 2020
Mylan and Development Partner, Synthon, Win Significant EPO Ruling Related to Copaxone® 40mg/mL
read more
02 jul 2019
BC Partners to Acquire Synthon International Holding B.V.
read more
05 oct 2017
Regulatory Approval in Europe granted for Synthon’s glatiramer acetate 40 mg/ml
read more
13 sept 2017
European Patent Office decides in Synthon’s favor in glatiramer patent case
read more
12 abr 2016
Synthon obtains approval for glatiramer acetate 20 mg/mL in Europe
read more
03 ago 2015
Pfizer and Synthon Enter Into U.S. Commercialization Agreement for Potential Generic Treatment of Multiple Sclerosis
read more
28 abr 2015
Synthon Announces Successful Outcomes from the Open-label extension of the Phase III GATE Study of Synthon’s Glatiramer Acetate
read more
09 oct 2014
Synthon Announces Filing of Glatiramer Acetate 40 mg/mL ANDA Containing a Paragraph IV Certification
read more
15 abr 2014
Synthon obtains European approvals for sevelamer
read more
27 mar 2014
Synthon announces successful outcome of the Phase III GATE study with its generic glatiramer acetate
read more
← Previous
1
(current)
2
Next →
Press contact
Corporate Communications
E
communications@synthon.com
Share this page
Archive
All
enero 2021
septiembre 2020
julio 2019
octubre 2017
septiembre 2017
abril 2016
agosto 2015
abril 2015
octubre 2014
abril 2014
marzo 2014
mayo 2012
abril 2012
enero 2012
diciembre 2011
noviembre 2011
julio 2011